Overview

Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients with Inflammatory Bowel Disease

Status:
NOT_YET_RECRUITING
Trial end date:
2031-09-01
Target enrollment:
Participant gender:
Summary
This 3+3 dose escalation pilot trial will assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in the Inflammatory Bowel Disease (IBD) patient population.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Brigham and Women's Hospital
Treatments:
Xylitol